CXCL8 and familial pancreatic carcinoma: With regard to pancreatic cancer, Zhang et al. highlighted how CXCL8 promoted murine TAM tracking in pancreatic cancer tumors, limiting the efficacy of anti-programmed death 1 (anti-PD1) ICI therapy [39].